Amgen’s Platelet Booster Faces FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk management plan is likely focus of March 12 ODAC meeting.
You may also be interested in...
FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use
GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.
FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use
GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.
FDA Panel Backs Amgen’s Nplate For Chronic Immune Thrombocytopenic Purpura
The platelet producer could have an important role in chronic ITP management, Oncologic Drugs Advisory Committee says.